Embla Medical hf: Interim Report Q3 2026
Announcement no. 51/2026 Interim Report Q3 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q3 2026 were USD 250 million, representing 5% reported growth and 4% organic growth. Growth was driven by Prosthetics & Neuro Orthotics, with strong performance in EMEA, partially offset by softer results in Americas…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


